Antibe Therapeutics utilizes a proprietary hydrogen sulfide platform to develop next-generation anti-inflammatory drugs that target pain and inflammation associated with various medical conditions. Their approach aims to enhance the therapeutic efficacy of existing medications while minimizing side effects, addressing the need for safer, non-addictive analgesics.
Funding
$31.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current anti-inflammatory drugs often come with significant side effects, including gastrointestinal issues and the potential for addiction, creating a need for safer and non-addictive alternatives for managing pain and inflammation. Existing treatments may also lack optimal efficacy for a wide range of medical conditions.
Solution
Antibe Therapeutics is developing next-generation anti-inflammatory drugs using a proprietary hydrogen sulfide platform. This platform aims to enhance the therapeutic effects of existing medications while significantly reducing adverse side effects. By harnessing the beneficial effects of hydrogen sulfide, Antibe is creating therapies that target pain and inflammation arising from various medical conditions. The company's approach leverages over 20 years of research into the clinical applications of hydrogen sulfide.
Target Audience
The primary target audience includes patients suffering from pain and inflammation associated with various medical conditions, as well as healthcare providers seeking safer and more effective treatment options.
Features
- Proprietary hydrogen sulfide platform technology
- Development of non-addictive analgesics
- Targeting pain and inflammation from a wide range of medical conditions
- Enhanced therapeutic efficacy compared to existing medications
- Reduced side effects profile